A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction.

Trial Profile

A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2014

At a glance

  • Drugs Colestipol (Primary) ; Ezetimibe (Primary) ; Niacin (Primary) ; HMG-CoA reductase inhibitors
  • Indications Hyperlipidaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top